Equity Research on Forest Laboratories Inc. and Endo Health

Equity Research on Forest Laboratories Inc. and Endo Health Solutions
Inc. - Patent Expiries and New Releases Lead to Mixed Results for
Drug Manufacturers 
JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 07/30/12 -- 
www.StockCall.com offers free research on Forest Laboratories Inc.
(NYSE: FRX) and Endo Health Solutions Inc. (NASDAQ: ENDP) from the
Drug Manufacturers - Other industry. Access these reports by clicking
on the links below or by copy and pasting those to your address bar.  
The drug manufacturers industry, which features companies such as
Forest Laboratories Inc. and Endo Health Solutions Inc. continues to
be negatively impacted by patent expirations. Several major
brand-name drugs have lost exclusivity as of late, and the results
are appearing on company financials.  
StockCall.com is an online platform where investors doing their
due-diligence on the Drug Manufacturers - Other industry can have
easy and free access to our analyst research and opinions on Forest
Laboratories Inc. and Endo Health Solutions Inc. To see how companies
in this industry have grown over the past years and how they are
expected to perform in the future, please visit the link below. 
In the case of Forest Laboratories, the company recently reported
that earnings from its fiscal 1st quarter came in at $55.3 million,
down substantially from earnings of $258.1 million achieved during
the same quarter last year. One reason for the decline was the loss
of exclusivity for Lexapro. Endo Health has also been dealing with
challenges stemming from losses of exclusivity. Register now to have
free access to our report on Endo Health Solutions Inc., and to do so
please click the link below. 
In an attempt to improve sales and grow revenues, companies in the
industry have been working hard on releasing new products. Forest
Laboratories together with Almirall S.A. have recently had success in
this regard, stating that the FDA has approved Tudorza(TM)
Pressair(TM) for the treatment of Bronchospasm associated with
chronic obstructive pulmonary disease. Investors and shareholders of
Forest Laboratories Inc. can simply register for our complimentary
reports by clicking on the link below. 
About StockCall.com  
StockCall.com is a financial website where investors can have easy,
precise and comprehensive research and opinions on stocks making the
Contact Person:
William T. Knight
Press spacebar to pause and continue. Press esc to stop.